Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China

BackgroundThe 2021 Chinese Expert Consensus on the Clinical Application of the Human Papillomavirus (HPV) Vaccine recommended vaccination for women who previously received ablative or excisional treatment for high-grade squamous intraepithelial lesion (HSIL). This study evaluates the cost-effectiven...

Full description

Bibliographic Details
Main Authors: Maosheng Zou, Hanting Liu, Huan Liu, Mengjie Wang, Zhuoru Zou, Lei Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1119566/full

Similar Items